Use this URL to cite or link to this record in EThOS:
Title: L-arginine modulation of host defences and response to neoadjuvant chemotherapy in patients with breast cancer
Author: Brittenden, J.
Awarding Body: University of Aberdeen
Current Institution: University of Aberdeen
Date of Award: 1995
Availability of Full Text:
Access from EThOS:
In this thesis, the effects of dietary supplementation with L-arginine (30 g/day for 3 days) on host defences in untreated patients with breast cancer were studied. L-arginine, significantly increased lymphocyte mitogenic reactivity to concanavalin A, phytohaemagglutinin and pokeweed mitogen. Natural killer (NK) and lymphokine-activated killer (LAK) cell cytotoxicity, were also significantly enhanced following L-arginine intake. However, no corresponding increase in the numbers of circulating NK and LAK cells was obtained. L-Arginine supplementation did not increase the level of serum cytokines. Subsequent studies, however, suggest that nitric oxide generation from L-arginine is required for optimal in vitro natural cytotoxicity and lymphocyte transformation. L-arginine supplementation in patients with breast cancer receiving CHOP chemotherapy resulted in a smaller and delayed onset of immunosuppression, compared with those patients who had chemotherapy only. L-arginine was able to repeatedly stimulate NK and LAK cell cytotoxicity in patients who were receiving chemotherapy. A pilot study of 45 patients demonstrated high clinical and pathological response rates following L-arginine-CHOP chemotherapy, suggesting that L-arginine may potentiate the effects of chemotherapy. In summary, dietary supplementation with L-arginine in patients with breast cancer significantly enhances host anti-cancer defences, and appears also to potentiate the effect of cell-cycle specific chemotherapeutic agents.
Supervisor: Not available Sponsor: Not available
Qualification Name: Thesis (M.D.) Qualification Level: Doctoral
EThOS ID:  DOI: Not available